The table below shows NovoCure Ltd's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$49.03M
-$26.37M
-$73.34M
$30.79M
$82.76M
$99.15M
Capital expenditure
$26.65M
$42.85M
$27.09M
$21.36M
$24.17M
$14.97M
Investing cash flow
$437.28M
-$140.24M
$184.15M
-$139.96M
-$144.83M
-$472.85M
Dividends paid
-
-
-
-
-
NVCR operating cash flow (10-K history)
NovoCure Ltd reported operating cash flow of -$49.03M for fiscal year 2025. That is down 85.9% from -$26.37M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$107.59M (FY 2016) to -$49.03M. Figures come from the company's audited annual reports as filed with the SEC.
